Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
Want to see AU:ATH full AI Analyst Report?
ATH Stock Chart & Stats
AU$0.01
>-AU$0.01(-10.00%)
At close: 4:00 PM EST
AU$0.01
>-AU$0.01(-10.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume25.42M
Average Volume (3M)16.33M
Market Cap
AU$97.88M
Enterprise ValueAU$48.84M
Total Cash (Recent Filing)AU$49.20M
Total Debt (Recent Filing)AU$163.91K
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding10,875,416,000
10 Day Avg. Volume24,202,939
30 Day Avg. Volume16,327,471
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.01Price Target Upside0.00%
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$3.30M
Bulls Say, Bears Say
Bulls Say
Proprietary Lead ProgramsAlterity's proprietary iron-modulating small-molecule programs represent a durable competitive asset: an IP-backed, mechanism-focused pipeline addressing an unmet neurodegenerative indication (MSA). Clinical-stage positioning and a differentiated mechanism can materially de-risk value if trials progress, supporting long-term strategic optionality and partner interest.
Minimal Financial LeverageExtremely low leverage reduces solvency risk and preserves flexibility during multi-year clinical programs. With minimal interest burden, management can prioritize R&D spending and strategic partnerships without outsized fixed obligations, which is a durable balance-sheet strength through clinical and regulatory cycles.
Robust Top-line GrowthSustained 46% revenue growth signals expanding funding or collaboration inflows that support R&D activities. Durable top-line expansion, if recurring or repeatable through partnerships/grants, helps extend runway and validates external interest in the platform, improving the company's ability to advance programs over the next several quarters.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow indicate ongoing cash burn from R&D and operations. Over a 2–6 month horizon this reduces runway, raises dependence on external financing, and increases the probability of dilutive capital raises, which can constrain long-term program execution and strategic investments.
Persistent UnprofitabilityNegative margins and an inability to generate operating profits reflect structural cost intensity vs. revenue. This persistent unprofitability limits internal cash generation, pressures ROE, and means the company must rely on external capital to fund growth, creating execution and dilution risks that persist beyond short-term cycles.
Reliance On Capital RaisesDependence on equity and financing to fund trials and operations creates ongoing dilution and exposes program timelines to market funding conditions. Without recurring commercial revenue, strategic flexibility is constrained, making long-term planning and hiring vulnerable to capital markets and increasing investor sensitivity to execution milestones.
Alterity Therapeutics News
ATH FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Alterity Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is AU$97.88M.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 277 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.001 earnings per share for the quarter, the consensus estimate of -AU$0.001 by AU$0.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently same.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 10,875,416,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of -AU$0.001 in its last earnings report, expectations of -AU$0.001. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.01 (0.00% )
AU$0.01 (0.00% )
Blogger Sentiment
Bullish
AU:ATH Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics (ATH) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, primarily targeting conditions such as Parkinson's disease and Alzheimer's disease. The company leverages its proprietary drug discovery platform to identify and develop small molecule therapies aimed at modifying disease progression and improving patient outcomes. Alterity is dedicated to advancing its clinical programs and expanding its pipeline of novel treatments to address significant unmet medical needs in the neurology sector.
ATH Stock 12 Month Forecast
Average Price Target
AU$0.01
▲(0.00% Upside)
Technical Analysis
Actinogen Medical
―
Cynata Therapeutics Limited
―
Tryptamine Therapeutics
―
Living Cell Technologies
―
Neuren Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---